Controlled drug delivery for superior treatment.

For patients, worldwide.

The specialty pharmaceutical company AMW supplies patients with biodegradable drug delivery systems for value-added and cost-effective therapies. With state-of-the-art production facilities in Germany, we cover the entire pharmaceutical value chain. Our employees, with their individual ideas and skills, are crucial to our success.

More about us

Join the team!

Click here to go to our AMW job portal

Our focus

Research & Development

Cutting-edge technology and know-how in extrusion: AMW’s technology platform as the basis for our growing development pipeline of drug delivery systems

Learn more

Products

Our implants goserelin and leuprorelin for the treatment of hormone-sensitive tumors

Learn more

Services

We support our pharma and biotech partners locally and globally – from technology collaboration to contract development

Learn more

We cover the entire value chain for drug delivery systems: from (co-)development to manufacturing and international commercialization via direct sales and out-licensing.

Latest News

1. July 2024

AMW Appoints Additional Experts for Drug Delivery Systems to its Scientific Advisory Board

Warngau, Germany, July 1, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Miriam Breunig, Senior Academic Councillor at the University of Regensburg’s Department of Pharmaceutical Technology, and Prof. Karsten Mäder, Professor of Pharmaceutics at Martin Luther University Halle-Wittenberg, as members to AMW’s Scientific […]

3. June 2024

AMW Again Reports Record Financial Results 2023, CEO Philipp Karbach Becomes Shareholder, Investment Program For Employees Launched

Warngau, June 3, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today reported financial results for the year ended December 31, 2023. AMW posted a 2023 consolidated record revenue of EUR 29.4 million and achieved operating profitability for the second consecutive year. In addition, the Company reported a partial […]

15. May 2024

AMW Receives Notified Body Opinion by TÜV SÜD for its Leuprorelin Implant in Pre-Filled Syringe

Warngau, Germany, May 15, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has received the final report of the Notified Body Opinion (NBO) for its leuprorelin implant in pre-filled syringes. The NBO completes a diligent conformity review procedure by a notified body, in this case […]

All News & Events